Recent investigations have revealed financial relationships between pharmaceutical companies and Pharmacy Benefit Managers (PBMs) that may have influenced opioid prescription practices. These payments, the nature and extent of which are still under scrutiny, raise concerns about potential conflicts of interest and their impact on the opioid crisis. Ongoing legal and regulatory actions are seeking to clarify the details of these arrangements and their consequences.